Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
ADNOC Gas Targets Up to $4B Profit in 2026 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
MEDFORD, N.Y., Feb. 22, 2018 -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2017 after the close of trading on Thursday, March 8, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by dialing 877-407-0778 from the US or 201-689-8565 from outside the US. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at www.chembio.com. A telephone replay will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 26056 until 4:30pm ET on Thursday, March 15, 2018.
Contact:
Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
[email protected]
